Literature DB >> 10468934

Amniotic fluid levels of dimeric inhibins, pro-alpha C inhibin, activin A and follistatin in Down's syndrome.

E M Wallace1, D D'Antona, C Shearing, L W Evans, P Thirunavukarasu, J P Ashby, M Shade, N P Groome.   

Abstract

OBJECTIVE: In the second trimester of pregnancy, inhibin A is significantly increased in maternal serum and decreased in amniotic fluid in Down's syndrome pregnancies compared to normal. We wished to further evaluate the levels of inhibin A, inhibin B, pro-alpha C inhibin, activin A and the binding protein follistatin in amniotic fluid in Down's syndrome and control pregnancies.
DESIGN: Case-matched control study. PATIENTS: 29 Down's syndrome and 290 chromosomally normal control pregnancies were identified from records and amniotic fluid, collected at second trimester amniocentesis, retrieved from routine storage for analysis. MEASUREMENTS: Inhibin A, inhibin B, pro-alpha C inhibin, total activin A and follistatin were measured using sensitive and specific enzyme linked immunosorbent assays.
RESULTS: The median (10th-90th percentiles) amniotic fluid inhibin A level in the control pregnancies increased from 334 (122-553) ng/l at 14 weeks' to 695 (316-1475) ng/l at 19 weeks' gestation. The corresponding figures for inhibin B and the alpha-subunit precursor inhibin pro-alpha C were 632 (185-1354) and 2062 (1237-3381) ng/l, respectively at 14 weeks' and 2439 (748-5307) and 3115 (2021-6567) ng/l, respectively at 19 weeks' gestation. Total activin A increased from 3795 (1554-5296) at 14 weeks' to 5086 (3059-8224) at 18 weeks' gestation. Expressed as multiples of the median (MoM) the median (95% CI) amniotic fluid levels of inhibin A, inhibin B, pro-alpha C inhibin and acitivin A in the Down's syndrome samples were 0.77 (0.59-0.85), 0.94 (0.63-1.23), 0.77 (0.49-0.84) and 0.77 (0.53-0.87), respectively. Compared to controls the levels of inhibin A, pro-alpha C inhibin and activin A were significantly lower in Down's syndrome pregnancies (P < 0.01, Mann-Whitney U test). Follistatin levels in the controls declined slightly from 2106 (1421-3538) ng/l at 14 weeks' to 1600 (1281-2543) ng/l at 18 weeks' gestation. Levels in the Downs' syndrome pregnancies were similar to controls.
CONCLUSIONS: The data suggest that the production, secretion or metabolism of the inhibin alpha- and beta A-subunits is altered in Down's syndrome pregnancies in the second trimester.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10468934     DOI: 10.1046/j.1365-2265.1999.00716.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

1.  Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma.

Authors:  Christopher W Seder; Wibisono Hartojo; Lin Lin; Amy L Silvers; Zhuwen Wang; Dafydd G Thomas; Thomas J Giordano; Guoan Chen; Andrew C Chang; Mark B Orringer; David G Beer
Journal:  Neoplasia       Date:  2009-04       Impact factor: 5.715

2.  Modulation of amniotic fluid activin-a and inhibin-a in women with preterm premature rupture of the membranes and infection-induced preterm birth.

Authors:  Victor A Rosenberg; Irina A Buhimschi; Antonette T Dulay; Sonya S Abdel-Razeq; Emily A Oliver; Christina M Duzyj; Heather Lipkind; Christian M Pettker; Catalin S Buhimschi
Journal:  Am J Reprod Immunol       Date:  2011-10-13       Impact factor: 3.886

3.  Maternal serum and amniotic fluid inhibin A levels in women who subsequently develop severe preeclampsia.

Authors:  Shin-Young Kim; Hyun-Mee Ryu; Jae-Hyug Yang; Moon-Young Kim; Hyun-Kyong Ahn; Joong-Sik Shin; Jun-Seek Choi; So-Yeon Park; Jin-Mi Kim; Bom-Yi Lee; Do-Jin Kim
Journal:  J Korean Med Sci       Date:  2006-06       Impact factor: 2.153

4.  Discovery of novel serum biomarkers for prenatal Down syndrome screening by integrative data mining.

Authors:  Jeroen L A Pennings; Maria P H Koster; Wendy Rodenburg; Peter C J I Schielen; Annemieke de Vries
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.